Allakos ended the fourth quarter of 2024 with $81 million in cash and expects restructuring costs of $34–$38 million, primarily to be paid by mid-2025. The company estimates its cash reserves ...

Overview: Allakos Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting immunomodulatory receptors on immune effector cells for allergy, inflammatory ...

Allakos Inc. SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of ...

Allakos (ALLK) has entered into a definitive merger agreement whereby Concentra Biosciences will acquire Allakos for $0.33 in cash per share of Allakos common stock. Allakos’ Board of Directors ...

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra.

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses, struggling Allakos is welcoming a $0.33 per share buyout offer wi ...

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and ...

Morningstar brands and products Company Portfolio ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has ...

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory ...